Breast Cancer Clinical Trial
Official title:
Pilot RCT on Lifestyles Impact on Health Outcomes in the General Population Invited to Mammography and Colorectal Cancer Screening Programmes. (STI.li di VI.ta - Lifestyles) STI.VI.
The main study objective is to determine the feasibility and impact (effectiveness) of
intervention models for lifestyle changing (diet and physical activity) on health outcomes.
Women 50 to 54-year-old attending the local breast cancer screening and 58-year-old people
(both sexes) undergoing colorectal cancer screening are invited to participate in the study.
Compliers are randomized into 3 intervention groups (Diet, Physical Activity, and Physical
Activity and Diet) and into the 'usual care' Control group. Biological sampling (blood and
saliva) is collected from all participants. All participants undergo also anthropometric
measurements and fill in a self-administered validated questionnaire on their dietary and
physical activity habits. All enrolled subjects receive a booklet with basic information
about diet and physical activity. Subjects randomized to the 3 intervention groups are also
offered one theoretical and three training courses. The courses are specifically designed
for the different interventions proposed and aimed at reinforcing the educational counseling
and at supporting behavioral changes.
Follow-up is performed at 8 (intermediate follow-up) and 12-14 (final follow-up) months for
repeating anthropometric measurements and questionnaire filling and blood sampling (at the
final one).
The study aims to evaluate the effectiveness of intervention models on diet and physical
activity.
The study randomizes eligible subjects into four groups: Diet group, Physical Activity
group, Physical Activity and Diet group and "Usual Care" control group. To each group a
specific intervention is delivered, consisting of counselling, informative material, and
dedicated training.
All participants (with the exception of the control group) receive a basic counselling by
field experts. Afterwards they are offered an advanced training including more specific and
detailed actions.
An information booklet specifically developed for this study is distributed to all
participants. The booklet contains general information on primary prevention, based on the
most reliable and updated bibliographic sources on diet and physical exercise.
Together with the letter of screening invitation eligible men and women receive the proposal
to participate in the STI.VI. study. Participation to screening is not considered a
prerequisite for study participation. A direct phone number and e-mail address are given for
extra information.
At the time of screening A screening receptionist asks people who received the STI.VI.
invitation (identified through a flag) whether they are interested in the STI.VI. study and
therefore refers them to the STI.VI. desk.
At the STI.VI. desk, trained research assistants give further explanations and additional
material (patient information sheet, informed consent form and the STI.VI. questionnaire).
If informed consent is signed, an appointment is fixed for anthropometric measurements and
for taking blood and saliva samples.
People are asked to fill in the questionnaire and to hand it back at the time of the blood
sampling.
The STI.VI. questionnaire consists of 5 sections (physical activity, dietary habits, smoking
habits, general health conditions, and general information) in order to collect baseline
information on lifestyle habits. Type, amount and frequencies of dietary consumptions and
physical activities are collected. The questionnaire also investigates the perception of
one's own lifestyle and an motivation towards change.
In this study phase all participants are randomly allocated to the 4 study groups.
This is achieved through a permuted block design with block size of 12, 16, and 20 units
width (W.F. Rosenberger, J. Lachin. Randomization in clinical trials: theory and practice.
Wiley and sons, 2002, pag. 57). This method allows an almost complete uniform distribution
of the randomisation groups in every moment of the study; this is necessary in order to
simplify the subsequent courses management (see below). Participants are told about their
group allocation at the time of biological sampling / anthropometric measurements, only.
At baseline appointment.
Participant subjects undergo anthropometric measurements. The following information are
collected:
- Reproductive and eventual menopause history (women only)
- Eventual drug therapy under way,
- Height,
- Body composition,
- Waist circumference
- Arterial pressure. Then participants undergo blood drawing. Two types of blood samples
are drawn: one for immediate biochemical analysis and another to be frozen. The freshly
blood is used for instantaneous examinations for the following clinic-biochemical
parameters: Insulin, Glucose, Total Cholesterol, LDL,HDL, Triglycerides, Minerals
(Sodium, Potassium, Calcium, Iron), IGF-I, Testosterone, 17-ß-Estradiol, SHBG. These
analyses are made for women invited to mammography screening while for people invited
to colorectal screening supplemental tests are made also for vitamin D, 25 OH, PRC and
high sensitive PRC.
Cryopreserved blood samples are stored in a bio-bank for epigenetic, metabolomics and
metabonomics analyses. Bio-banking includes a security system and a data base specifically
implemented for samples storage and traceability.
About 3 ml of saliva are also collected to investigate variations in genetic and metabolic
parameters. Saliva samples are cryopreserved with the same modalities as blood samples.
Immediately after biological sampling / anthropometric measurements a short counselling
takes place. Trained counsellors answer all eventual questions on the study posed by
participants and inform them on the next steps. They also deliver to all participants a
basic booklet containing general information on primary prevention, based on the most
reliable and updated bibliographic sources on diet and physical exercise (World Cancer
Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity,
and the prevention of cancer: a global perspective. Washington, DC: AICR, 2007; WHO, Move
for Health, 2002; EU Working Group "Sport and Health", EU Physical Activity Guidelines,
2008).
Follow-up phase
Two follow-ups are planned:
• Intermediate, after 8 months since biological sampling / anthropometric measurements (the
exact date is reckoned calculating 6 months + the average intervention duration ± 2 weeks,
for managing reasons): it consists of repeating anthropometric measurements and
questionnaire filling, and counselling.
All participants are contacted by letter and/or telephone, inviting them to contact the
study secretariat in order to fix an appointment for repeating anthropometric measurements
and questionnaire filling; during the follow-up visit trained counsellors verify
participants' compliance with the provided recommendations, examine eventual encountered
difficulties and provide support if needed.
• Final, after 6 months from intermediate follow-up (i.e., after 14 months since biological
sampling / anthropometric measurements): it consists of repeating anthropometric
measurements, biological sampling, and questionnaire filling, and counselling.
All participants are contacted by letter and/or telephone, inviting them to contact the
study secretariat in order to fix an appointment for repeating once again anthropometric
measurements, questionnaire filling and also biological sampling.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |